IDStewardship

NOVEMBER 18, 2024

This article discusses ways to celebrate the annual observance of antibiotic awareness week 2024. Written by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Each year for one week the United States Centers for Disease Control and Prevention (CDC) observes U.S. Antibiotic Awareness Week (USAAW) and encourages others to participate in the event. The USAAW theme this year is “Fighting Antibiotic Resistance Takes All Of Us.” This same week the World Health Organization observes World Antimic

Hospitals

Pharmafile

NOVEMBER 18, 2024

This month, the Chalmers University of Technology in Sweden have published the results of a study demonstrating that resistant bacteria, when paired with material equipped with antibacterial peptides, can regain susceptibility to antibiotics. The study, conducted in a laboratory environment, concluded that antibiotics – such as oxacillin – could achieve an increase in their bactericidal […] The post Antibacterial peptides instrumental in efficiency against resistant bacteria appeared first

Fierce Pharma

NOVEMBER 18, 2024

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in a bid to boost production for a long-approved transplant treatment and a | Sanofi has unveiled a 40 million euro investment at its Lyon Gerland biomanufacturing site in France. The cash infusion will help bolster local production of the company’s polyclonal antibody Thymoglubulin for kidney transplant rejection, as well as expected future capacity needs for the type 1 diab

European Pharmaceutical Review

NOVEMBER 18, 2024

Sanofi is investing over €40 million in its Lyon Gerland site, supporting antibody bioproduction in France. A portion of this, €25 million, will be directed toward production and development of Sanofi’s second generation of its polyclonal antibody Thymoglubulin. It is used for transplantation and is manufactured exclusively at the Lyon Gerland site, Sanofi stated.

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

pharmaphorum

NOVEMBER 18, 2024

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 receptor agonist class.The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly's drug cut the risk of cardiovascular mortality and worsening heart failure events by 38% over a median follow-up of roughly two years.

The FDA Law Blog

NOVEMBER 18, 2024

By Jennifer D. Newberger & Jeffrey N. Gibbs — On Thursday, November 14, President-Elect Trump announced his pick of Robert Kennedy, Jr., for Secretary of Health and Human Services (HHS). Although not altogether surprising, the formality of an official announcement still came as a shock to many of us who work in areas regulated by HHS, as well as to many others in the public health arena.

FDA

PharmaVoice

NOVEMBER 18, 2024

With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.

Drug Topics

NOVEMBER 18, 2024

Michael Ganio, PharmD, BCPS, FASHP, discusses how the industry can become more resilient.

Pharmacy Times

NOVEMBER 18, 2024

The disorder presents as severe lung disease, with lung transplantation as the only current therapeutic option for long-term survival.

FDA

Drug Topics

NOVEMBER 18, 2024

Researchers evaluated the efficacy of a self-managed intervention vs enhanced usual care.

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

PharmaVoice

NOVEMBER 18, 2024

Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma.

Drug Topics

NOVEMBER 18, 2024

A PDUFA date for acoramidis has been set for November 29, 2024.

Pharmacy Times

NOVEMBER 18, 2024

Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.

Drug Topics

NOVEMBER 18, 2024

Continued methylphenidate or atomoxetine use may be safe, but additional studies are needed.

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

NOVEMBER 18, 2024

Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. | Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring.

Drug Topics

NOVEMBER 18, 2024

Drug Topics sat down with Adam J. James, PharmD, to discuss his journey from chain pharmacist to innovation leader at Rite Aid.

Immunization

Pharmacy Times

NOVEMBER 18, 2024

Rachel Chandra, PharmD, MPH, FASHP, shares insight into the VALOR-QI program.

Drug Topics

NOVEMBER 18, 2024

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, also discusses ways community pharmacists can collaborate with other healthcare professionals to enhance diabetes management.

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

NOVEMBER 18, 2024

Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.

STAT

NOVEMBER 18, 2024

CHICAGO — This year’s scientific sessions on the latest research in cardiovascular disease began not with the buzzy new obesity drugs but with a sobering look at progress stalling or even reversing in common chronic illnesses. The overture to the American Heart Association’s conference, coming as the organization celebrates its 100th year, began with Valentin Fuster of Mount Sinai Hospital lamenting the predicted shift in overall cardiovascular disease burden,  worsenin

Hospitals

Pharmacy Times

NOVEMBER 18, 2024

The pipeline of hallucinogenic and nonhallucinogenic psychedelic medicines Is exploding.

Fierce Healthcare

NOVEMBER 18, 2024

As CVS Health pushes to turn around its financial fortunes, it has entered into a deal with key investor Glenview Capital Management that will add four members to its board of directors. | As CVS Health pushes to turn around its financial fortunes, it has entered into a deal with key investor Glenview Capital Management that will add four members to its board of directors.

Fierce Pharma

NOVEMBER 18, 2024

Robert F. | In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr. may not rock the boat as much as feared for the biopharma industry.

FDA

pharmaphorum

NOVEMBER 18, 2024

Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares

Fierce Pharma

NOVEMBER 18, 2024

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters. | The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters.

pharmaphorum

NOVEMBER 18, 2024

Using AI-powered PanEcho software for screening ECGs could deliver results more quickly and allow treatment to be started earlier.

Pharmaceutical Technology

NOVEMBER 18, 2024

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

FDA

pharmaphorum

NOVEMBER 18, 2024

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company.A report in Spanish newspaper El Confidencial suggests that Brookfield is preparing to make a bid to take a 65% controlling stake in the drugmaker for €10.50 per share, worth around €7 billion ($7.4 billion).

The Checkup by Singlecare

NOVEMBER 18, 2024

Left untreated, attention deficit hyperactivity disorder ( ADHD ) can negatively impact relationships and school and work performance. Fortunately, there are several ADHD treatment options available. Stimulants such as Adderall , Vyvanse , Ritalin , and Concerta are commonly prescribed to increase focus and attention while boosting impulse control. Adderall ( amphetamine-dextroamphetamine ) and Vyvanse ( lisdexamfetamine dimesylate ) are both brand-name central nervous system (CNS) stimulants a

FDA

pharmaphorum

NOVEMBER 18, 2024

Shortly after a disappointing trial readout for Syndax's menin inhibitor Revuforj in one form of leukaemia, the company has claimed FDA approval in another

FDA

Pharmaceutical Technology

NOVEMBER 18, 2024

During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically diagnosed FCS,

pharmaphorum

NOVEMBER 18, 2024

AbbVie's Elahere is approved in EU, ending a 10-year wait for a new therapy for platinum-resistant ovarian cancer.

Pharmaceutical Technology

NOVEMBER 18, 2024

The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment of various retinal diseases.